Aucta Pharmaceuticals Inc

There are no reviews yet!
You can review this Business and help others by leaving a comment. If you want to share your thoughts about Aucta Pharmaceuticals Inc, use the form below and your opinion, advice or comment will appear in this space.

Aucta Pharmaceuticals LLC | ZoomInfo.com

Aucta Pharmaceuticals, Inc. is a research and technology based pharmaceutical company focusing on the development and commercialization of niche generic and bra...

Aucta Pharmaceuticals, Inc. - CMOCRO

Aucta Pharmaceuticals, Inc. is a technology-based company focusing on the development and commercialization of Branded Specialty Products. Aucta is a pharmaceutical company creating better products of proven molecules using 505(b)(2) regulatory pathway.

Aucta Pharmaceuticals and Oakrum Pharma Announce Product ...

About Aucta Pharmaceuticals, Inc. ... (732)640-0030 pr@auctapharma.com. Related Articles. More articles issued by Aucta Pharmaceuticals, Inc. More articles related to: Partnerships.

Aucta Pharma | www.inknowvation.com

Aucta Pharmaceuticals, Inc. (AUCTA, Latin-improved, enhanced) is a technology based company focusing on the development and commercialization of Branded Specialty Products. Aucta is a pharmaceutical company creating better products of proven molecules using 505(b)(2) regulatory pathway.

Aucta Receives its First Product Approval and Launches ...

Jul 16, 2018 · About Aucta Pharmaceuticals Inc. Aucta Pharmaceuticals, Inc. (AUCTA, Latin-improved, enhanced) is a technology based product company focusing on development and commercialization of niche generic ...

Aucta Pharmaceuticals | Crunchbase

Aucta Pharmaceuticals is a provider of a drug development platform intended to improve drug delivery.

Barr Pharmaceuticals in Woodbridge, NJ with Reviews - YP.com

Find 978 listings related to Barr Pharmaceuticals in Woodbridge on YP.com. See reviews, photos, directions, phone numbers and more for Barr Pharmaceuticals locations in Woodbridge, NJ.

Topical Sirolimus Ointment for Cutaneous Angiofibromas in ...

The objective of this study is to evaluate the safety and efficacy of sirolimus (0.2% and 0.4% formulations) and its vehicle when applied topically once daily for 12 weeks for the treatment of cutaneous angiofibromas in pediatric subjects with tuberous sclerosis complex (TSC). This is a Phase 2 ...

Aucta Pharmaceuticals宣布将进行产品开发和商业化合作 - 企媒在线 -企业资讯第一媒体网站

Aucta Pharmaceuticals, Inc.是一家以研究和技术为基础的制药公司，专注于利基仿制药和品牌特种药的开发和商业化。 ... (732)640-0030 ...